# Clinical Guidelines for CRS Risk Stratification and Management

## Overview

This document provides clinical practice guidelines for managing Cytokine Release Syndrome (CRS) in patients receiving Epcoritamab, based on the survival analysis findings and established clinical protocols.

---

## ğŸ¯ Risk Stratification System

### Weight-Based Risk Assessment (Novel Finding)

Based on our analysis, patient body weight is the primary predictor of CRS risk.

| Weight Category | CRS Risk | HR (vs. 60kg) | Clinical Classification |
|-----------------|----------|---------------|------------------------|
| **<60 kg** | **HIGH** | 1.00 (baseline) | Enhanced monitoring required |
| **60-80 kg** | **MODERATE** | 0.85 (15% â†“) | Standard monitoring |
| **>80 kg** | **LOWER** | 0.73 (27% â†“) | Standard monitoring |

### Comprehensive Risk Score

```
Risk Score Calculation:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Risk Factor                         â”‚ Points â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Weight <60 kg                       â”‚   +2   â”‚ â­ NEW
â”‚ Age >65 years                       â”‚   +1   â”‚
â”‚ Polypharmacy (â‰¥3 drugs)             â”‚   +1   â”‚
â”‚ Prior life-threatening event        â”‚   +2   â”‚
â”‚ Prior hospitalization for AE        â”‚   +1   â”‚
â”‚ ECOG status â‰¥2 (if available)       â”‚   +1   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Risk Classification:
  Score 0-1:  LOW risk (not observed in this cohort)
  Score 2-3:  MODERATE risk â†’ 30.7% CRS rate
  Score â‰¥4:   HIGH risk â†’ 36.9% CRS rate
```

---

## ğŸ“Š CRS Grading System

### ASTCT Consensus Grading (Lee et al., 2019)

| Grade | Fever | Hypotension | Hypoxia | Management Level |
|-------|-------|-------------|---------|------------------|
| **1** | â‰¥38Â°C | None | None | Outpatient possible after 24h |
| **2** | â‰¥38Â°C | Responsive to fluids or low-dose vasopressor | FiOâ‚‚ <40% | Inpatient monitoring |
| **3** | â‰¥38Â°C | Requiring high-dose or multiple vasopressors | FiOâ‚‚ â‰¥40% | ICU admission |
| **4** | â‰¥38Â°C | Life-threatening hypotension | Mechanical ventilation | ICU + aggressive intervention |

### Our Cohort Distribution

| Grade | Count | Percentage | Severity Classification |
|-------|-------|------------|------------------------|
| **Any CRS** | 344 | 34.4% | Total CRS rate |
| **Grade 1-2** | 316 | 31.6% | Mild-Moderate CRS |
| **Grade 3-4** | 28 | 2.8% | Severe CRS (requires ICU) |

---

## â° Temporal Monitoring Protocol

### Critical 24-Hour Window

**Key Finding:** 100% of CRS events occurred within the first 24 hours post-dose.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚              TEMPORAL MONITORING PROTOCOL                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  0-4 Hours Post-Dose:        HIGHEST RISK PERIOD           â”‚
â”‚  â”œâ”€ Vital signs q15min                                     â”‚
â”‚  â”œâ”€ Patient in observation unit                            â”‚
â”‚  â””â”€ Tocilizumab immediately available                      â”‚
â”‚                                                             â”‚
â”‚  4-12 Hours Post-Dose:       HIGH RISK PERIOD              â”‚
â”‚  â”œâ”€ Vital signs q30min                                     â”‚
â”‚  â”œâ”€ Continued inpatient observation                        â”‚
â”‚  â””â”€ ICU bed reserved for high-risk patients                â”‚
â”‚                                                             â”‚
â”‚  12-24 Hours Post-Dose:      MODERATE RISK PERIOD          â”‚
â”‚  â”œâ”€ Vital signs q1h                                        â”‚
â”‚  â”œâ”€ If no CRS, can consider discharge planning             â”‚
â”‚  â””â”€ Patient education on delayed symptoms (rare)           â”‚
â”‚                                                             â”‚
â”‚  >24 Hours Post-Dose:        MINIMAL RISK                  â”‚
â”‚  â”œâ”€ CRS risk approaches zero                               â”‚
â”‚  â”œâ”€ Can safely discharge if no Grade â‰¥1 CRS               â”‚
â”‚  â””â”€ Outpatient follow-up in 7 days                         â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ¥ Risk-Stratified Management Protocols

### HIGH RISK Patients (Score â‰¥4 OR Weight <60kg)

#### Pre-Treatment

```
â˜‘ Mandatory inpatient administration
â˜‘ ICU bed reserved and available
â˜‘ Tocilizumab (8 mg/kg) on-site in pharmacy
â˜‘ Dexamethasone available at bedside
â˜‘ Patient counseled on CRS symptoms
â˜‘ Consider prophylactic:
   - Antihistamine (diphenhydramine 25-50mg)
   - Antipyretic (acetaminophen 650mg)
   - Fluid pre-hydration (500-1000 mL NS)
```

#### During Administration

```
â˜‘ Monitor in observation unit or step-down unit
â˜‘ Continuous pulse oximetry
â˜‘ Cardiac monitoring
â˜‘ Vital signs every 15 minutes Ã— 4 hours
â˜‘ Then vital signs every 30 minutes Ã— 8 hours
â˜‘ Then vital signs every 1 hour Ã— 12 hours
```

#### Post-Dose Management

```
â˜‘ Minimum 24-hour inpatient observation
â˜‘ Extend to 48 hours if any Grade 1 symptoms
â˜‘ ICU transfer if Grade â‰¥3
â˜‘ Early tocilizumab for Grade 2
â˜‘ Discharge criteria:
   - No fever for 12+ hours
   - Vital signs stable
   - Patient ambulatory
   - Reliable follow-up arranged
```

---

### MODERATE RISK Patients (Score 2-3)

#### Pre-Treatment

```
â˜‘ Inpatient administration for first dose
â˜‘ Tocilizumab available within 2 hours
â˜‘ ICU bed on standby (not reserved)
â˜‘ Patient counseled on CRS symptoms
â˜‘ Consider prophylactic antipyretic
```

#### During Administration

```
â˜‘ Monitor in infusion center or observation unit
â˜‘ Vital signs every 30 minutes Ã— 4 hours
â˜‘ Then vital signs every 1 hour Ã— 8 hours
â˜‘ Pulse oximetry spot checks
```

#### Post-Dose Management

```
â˜‘ 24-hour observation
â˜‘ Can discharge if no Grade â‰¥1 CRS by 24h
â˜‘ Patient education on self-monitoring
â˜‘ 24/7 oncology contact provided
â˜‘ Follow-up call at 48 hours
```

---

## ğŸ’Š CRS Treatment Algorithm

### Grade 1 CRS

**Symptoms:** Fever â‰¥38Â°C only

```
Management:
1. Supportive Care
   â”œâ”€ Acetaminophen 650-1000 mg PO q6h PRN
   â”œâ”€ Fluid bolus 500 mL NS if needed
   â””â”€ Monitor vital signs q1h

2. Observation
   â”œâ”€ Continue monitoring for 24 hours
   â”œâ”€ Watch for progression to Grade 2
   â””â”€ Patient remains inpatient

3. No Immunosuppression
   â”œâ”€ Do NOT give tocilizumab for Grade 1
   â””â”€ Do NOT give corticosteroids for Grade 1

4. If persists >24h â†’ Re-evaluate as Grade 2
```

---

### Grade 2 CRS

**Symptoms:** Fever + hypotension responsive to fluids OR hypoxia (FiOâ‚‚ <40%)

```
Management:
1. TOCILIZUMAB (IL-6 Inhibitor)
   â”œâ”€ Dose: 8 mg/kg IV (max 800 mg)
   â”œâ”€ Infuse over 1 hour
   â”œâ”€ Can repeat Ã— 1 after 8 hours if no improvement
   â””â”€ Maximum 3-4 doses total

2. Supportive Care
   â”œâ”€ Fluid resuscitation: 500-1000 mL NS bolus
   â”œâ”€ Supplemental oxygen to maintain SpOâ‚‚ >92%
   â”œâ”€ Acetaminophen 650-1000 mg q6h
   â””â”€ Consider meperidine 25-50 mg for rigors

3. Monitoring
   â”œâ”€ Transfer to step-down unit or ICU
   â”œâ”€ Continuous cardiac monitoring
   â”œâ”€ Continuous pulse oximetry
   â”œâ”€ Vital signs q15min until stable
   â”œâ”€ Strict I/O monitoring
   â””â”€ Consider arterial line if hypotension persists

4. If No Improvement at 24h
   â”œâ”€ Consider adding corticosteroids
   â””â”€ Dexamethasone 10 mg IV q6h (off-label)
```

---

### Grade 3-4 CRS

**Symptoms:** High-dose vasopressors OR FiOâ‚‚ â‰¥40% OR mechanical ventilation

```
Management:
1. IMMEDIATE ICU TRANSFER

2. TOCILIZUMAB + CORTICOSTEROIDS (Combination)
   â”œâ”€ Tocilizumab 8 mg/kg IV (give first)
   â”œâ”€ PLUS Dexamethasone 10 mg IV q6h
   â”‚  (or Methylprednisolone 1-2 mg/kg/day)
   â””â”€ Continue steroids until CRS resolves to Grade â‰¤1

3. Aggressive Supportive Care
   â”œâ”€ Vasopressors (norepinephrine, vasopressin)
   â”œâ”€ Mechanical ventilation if needed
   â”œâ”€ Arterial line for BP monitoring
   â”œâ”€ Central line for vasopressor administration
   â”œâ”€ Foley catheter for strict I/O
   â””â”€ Consider Swan-Ganz catheter if cardiogenic shock

4. Hold Epcoritamab
   â”œâ”€ Do NOT give subsequent doses until CRS resolves
   â”œâ”€ Restart at reduced dose after recovery
   â””â”€ Consider permanent discontinuation for Grade 4

5. Multidisciplinary Management
   â”œâ”€ Oncology
   â”œâ”€ Critical care
   â”œâ”€ Infectious disease (rule out sepsis)
   â””â”€ Cardiology (if cardiac dysfunction)
```

---

## ğŸ”¬ Laboratory Monitoring

### Baseline (Pre-Treatment)

```
â˜‘ Complete Blood Count (CBC) with differential
â˜‘ Comprehensive Metabolic Panel (CMP)
â˜‘ Liver Function Tests (LFTs)
â˜‘ Coagulation panel (PT/INR, aPTT)
â˜‘ C-Reactive Protein (CRP)
â˜‘ Ferritin
â˜‘ Lactate Dehydrogenase (LDH)
â˜‘ Fibrinogen

Optional (if biomarker study):
â˜‘ IL-6, IL-10, IFN-Î³
â˜‘ CCL17, CCL13, MCP-1
```

### During CRS Episode

```
â˜‘ CBC q6-12h (watch for cytopenias)
â˜‘ CMP q12-24h (electrolytes, renal function)
â˜‘ LFTs q24h (hepatotoxicity)
â˜‘ CRP, ferritin q24h (inflammatory markers)
â˜‘ Lactate q6h if Grade â‰¥2 (tissue perfusion)
â˜‘ Blood cultures if fever (rule out infection)
â˜‘ Coags if DIC suspected
```

### Biomarker Trends (if available)

| Biomarker | Grade 1 CRS | Grade 2 CRS | Grade 3-4 CRS |
|-----------|-------------|-------------|---------------|
| IL-6 | 5-50 pg/mL | 50-200 pg/mL | >200 pg/mL |
| Ferritin | 500-2000 ng/mL | 2000-10,000 ng/mL | >10,000 ng/mL |
| CRP | 10-50 mg/L | 50-150 mg/L | >150 mg/L |

---

## ğŸ“ Decision Support Algorithm

### When to Call for Help

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚               ESCALATION CRITERIA                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                        â”‚
â”‚  CALL PRIMARY ONCOLOGY TEAM:                           â”‚
â”‚  â˜ Fever â‰¥38Â°C developing                             â”‚
â”‚  â˜ Any Grade 1 CRS symptoms                           â”‚
â”‚  â˜ Patient anxiety or concern                         â”‚
â”‚                                                        â”‚
â”‚  ACTIVATE RAPID RESPONSE:                              â”‚
â”‚  ğŸš¨ Hypotension (SBP <90 mmHg)                        â”‚
â”‚  ğŸš¨ Hypoxia (SpOâ‚‚ <92% on room air)                   â”‚
â”‚  ğŸš¨ Altered mental status                             â”‚
â”‚  ğŸš¨ Respiratory distress                              â”‚
â”‚                                                        â”‚
â”‚  IMMEDIATE ICU TRANSFER:                               â”‚
â”‚  âš ï¸ Grade 3-4 CRS confirmed                           â”‚
â”‚  âš ï¸ Requiring vasopressors                            â”‚
â”‚  âš ï¸ Requiring FiOâ‚‚ >40%                               â”‚
â”‚  âš ï¸ No response to tocilizumab + fluids at 2h         â”‚
â”‚                                                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ“‹ Patient Education Materials

### Pre-Treatment Patient Counseling

**Topics to Cover:**

1. **What is CRS?**
   - "Your immune system may become very active after the medication"
   - "This can cause fever, low blood pressure, and breathing problems"
   - "We will watch you very closely for 24 hours"

2. **Symptoms to Report Immediately:**
   - âœ“ Fever or chills
   - âœ“ Dizziness or lightheadedness
   - âœ“ Shortness of breath
   - âœ“ Rapid heartbeat
   - âœ“ Confusion

3. **Monitoring Plan:**
   - "We will check your vital signs every 15-30 minutes at first"
   - "You will stay in the hospital for at least 24 hours"
   - "Most symptoms happen in the first day"

4. **Treatment Available:**
   - "We have medications ready to stop CRS (tocilizumab)"
   - "Most CRS is mild and responds quickly to treatment"
   - "An ICU bed is available if needed"

---

### Post-Discharge Instructions

**Give to Patient/Caregiver:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚        POST-EPCORITAMAB DISCHARGE INSTRUCTIONS       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                     â”‚
â”‚ You were treated with epcoritamab today.           â”‚
â”‚ Your risk of serious side effects is now very low. â”‚
â”‚                                                     â”‚
â”‚ CALL YOUR DOCTOR IMMEDIATELY IF:                    â”‚
â”‚ â€¢ Fever >100.4Â°F (38Â°C)                            â”‚
â”‚ â€¢ Dizziness or fainting                            â”‚
â”‚ â€¢ Trouble breathing                                â”‚
â”‚ â€¢ Fast heartbeat                                   â”‚
â”‚ â€¢ Confusion or drowsiness                          â”‚
â”‚                                                     â”‚
â”‚ FOLLOW-UP:                                          â”‚
â”‚ â€¢ We will call you in 48 hours                     â”‚
â”‚ â€¢ Return to clinic in 7 days                       â”‚
â”‚ â€¢ Call 24/7 hotline: [PHONE NUMBER]                â”‚
â”‚                                                     â”‚
â”‚ MEDICATIONS:                                        â”‚
â”‚ â€¢ Take acetaminophen 650mg as needed for fever     â”‚
â”‚ â€¢ Stay well-hydrated (8 glasses water/day)         â”‚
â”‚                                                     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ”„ Quality Improvement Metrics

### Suggested Tracking

| Metric | Target | Purpose |
|--------|--------|---------|
| **CRS incidence** | Monitor vs. 34.4% baseline | Track consistency |
| **Time to CRS onset** | Document all cases | Validate 24h window |
| **Grade 3-4 CRS rate** | <5% | Safety threshold |
| **Time to tocilizumab** | <30 min from Grade 2 | Process efficiency |
| **ICU admission rate** | <5% | Resource planning |
| **CRS-related mortality** | 0% | Safety endpoint |
| **Weight documentation** | 100% | Enable risk scoring |

---

## ğŸ“š References

1. **Lee, D. W., et al. (2019).** "ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells." *Biology of Blood and Marrow Transplantation*, 25(4), 625-638.

2. **Thieblemont, C., et al. (2022).** "Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Escalation in an Open-Label Phase I/II Trial." *Journal of Clinical Oncology*, 40(21), 2238-2247.

3. **Hutchings, M., et al. (2021).** "Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma." *Blood*, 137(21), 2892-2901.

4. **Hay, K. A., et al. (2017).** "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptorâ€“modified T-cell therapy for acute lymphoblastic leukemia." *Blood*, 130(21), 2295-2306.

5. **National Cancer Institute (NCI).** Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

---

## ğŸ“ Emergency Contacts

### Template for Institution

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      EPCORITAMAB CRS EMERGENCY CONTACTS      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                             â”‚
â”‚ Primary Oncology Team:      [PHONE]        â”‚
â”‚ Hematology Fellow on Call:  [PAGER]        â”‚
â”‚ ICU Attending:              [PHONE]        â”‚
â”‚ Pharmacy (Tocilizumab):     [PHONE]        â”‚
â”‚ Rapid Response Team:        [CODE]         â”‚
â”‚                                             â”‚
â”‚ Epcoritamab Protocol PI:    [PHONE]        â”‚
â”‚ After Hours Backup:         [PHONE]        â”‚
â”‚                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## âœ… Pre-Treatment Checklist

```
EPCORITAMAB ADMINISTRATION CHECKLIST

Patient Name: ________________  MRN: __________  Date: ________

â˜ Risk score calculated: ______ (Low/Moderate/High)
â˜ Patient weight documented: ______ kg
â˜ Pre-medications given:
   â˜ Acetaminophen 650-1000 mg PO
   â˜ Diphenhydramine 25-50 mg PO or IV (if ordered)
â˜ Baseline vitals obtained and documented
â˜ Baseline labs drawn (CBC, CMP, LFTs)
â˜ IV access established (18G or larger preferred)
â˜ Tocilizumab 8 mg/kg available on unit
â˜ Dexamethasone 10 mg vials available
â˜ ICU bed reserved (if high-risk patient)
â˜ Patient counseled on CRS symptoms
â˜ Consent obtained and documented
â˜ Monitoring plan communicated to nursing
â˜ Emergency contact numbers posted in chart

Infusion Start Time: ______  Completed: ______
Administered by: ____________  RN License: ______

POST-INFUSION MONITORING SCHEDULE:
â˜ Q15min Ã— 4 hours (0-4h)
â˜ Q30min Ã— 8 hours (4-12h)
â˜ Q1h Ã— 12 hours (12-24h)
â˜ 24-hour reassessment completed

Discharge Criteria Met:
â˜ No fever Ã— 12 hours
â˜ Vital signs stable Ã— 6 hours
â˜ Patient ambulatory
â˜ Discharge instructions given
â˜ Follow-up appointment scheduled

Discharge Time: ______  Discharged by: ____________
```

---

**Last Updated:** 2025-11-18  
**Version:** 1.0  
**Review Date:** 2026-11-18

**Clinical Use:** These guidelines are based on the survival analysis findings from this study combined with established CRS management protocols. Institutional protocols may vary. Always follow your institution's policies and procedures.

---

<div align="center">

**For questions or feedback on these guidelines, contact:**  
[Your Name] â€¢ [Institution] â€¢ [Email]

</div>

